Lundbeck Head of R&D denies allergy aspirations
Lundbeck's recently initiated recruitment of grass allergy sufferers for a phase I trial does not herald changing winds at the pharmaceutical firm – no allergy market conquest is in the cards, says Head of R&D at Lundbeck Johan Luthman.
by albert rønning-andersson, translated by daniel pedersen
It created ripples when it was recently uncovered that pharmaceutical firm Lundbeck is on the lookout for 36 grass allergy sufferers for a phase I study.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
